The EACR’s ‘Highlights in Cancer Research’ is a regular summary of the most interesting and impactful recent papers in cancer research, curated by the Board of the European Association for Cancer Research (EACR).
The list below appears in no particular order, and the summary information has been provided by the authors unless otherwise indicated.
Use the dropdown menu or ‘Previous’ and ‘Next’ buttons to navigate the list.
Pozzato, C. et al. EMBO Molecular Medicine. 16 (10): 2402 – 2426 (2024).
doi: 10.1038/s44321-024-00138-7.
Summary of the findings
Summary of the findingsLung cancer, particularly non-small cell lung cancer (NSCLC), is one of the leading causes of cancer deaths globally. Around 30% of NSCLC cases involve mutations in a gene called KRAS, which drives aggressive tumor growth and often leads to resistance against standard treatments. While new therapies targeting proteins like FAK (Focal Adhesion Kinase) show promise, many tumors develop resistance, limiting their effectiveness.
.
In this paper, Pozzato et al. investigated the mechanisms underlying FAK inhibitor resistance in NSCLC. By examining the contribution of the different regulatory phosphorylation sites on FAK they discovered that ERK5 and CDK5, two enzymes, play crucial roles in maintaining the tumor-promoting functions of FAK. Inhibition of ERK5 and CDK5 together was found to significantly reduce cancer cell growth and induce cell death by increasing oxidative stress and triggering DNA damage.
.
Prolonged FAK inhibitor treatment in NSCLC cells induces resistance via ERK5 upregulation, which sustains FAK signaling and promotes cell survival. Inhibiting ERK5 restores drug sensitivity, causing DNA damage and cancer cell death.
.
The findings suggest that targeting ERK5 alongside FAK may offer a promising strategy to combat drug resistance and enhance the efficacy of NSCLC therapies in patients with KRAS mutations.
.
.
Future impact
This study suggests that dual inhibition of ERK5 and FAK could become a transformative approach in treating KRAS-driven NSCLC by significantly enhancing the effectiveness of FAK inhibitors and reducing drug resistance, which is a common challenge in targeted cancer therapies. The findings could pave the way for combination therapies that may extend patient survival and improve quality of life. Future clinical trials could explore ERK5 inhibitors, which are not yet widely available, as potential partners in combination therapies for lung cancer and possibly other cancers where similar resistance mechanisms are at play.
.
